Literature DB >> 34380090

Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.

Dana A Schaar1, Filip Pirsl1, Noa Holtzman1, Seth M Steinberg2, Jeannette Nashed1, Claire Ruben1, Edward W Cowen3, Jacqueline W Mays4, Sandra Mitchell5, Alen Ostojic6, Pashna N Munshi7, Galen O Joe8, Leora E Comis8, Lindsay Morton9, Steven Z Pavletic10.   

Abstract

Subsequent cancer (SC) is a significant cause of morbidity and mortality in long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic graft-versus-host disease (cGVHD) and treatment-related immunosuppression have been recognized as risk factors for SC. This study sought to investigate the incidence and risk factors for SC in patients with established cGVHD, assessed separately for onset of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)-categorized into nonmelanoma skin cancer (NMSC)-and all cancers other than NMSC. Two hundred and four patients were enrolled in the prospective cross-sectional cGVHD Natural History Study and underwent comprehensive clinical evaluation. Patients were followed-up with an annual survey. The cumulative incidences of NMSC and cancers other than NMSC with competing risks were estimated separately, and transplantation- and cGVHD-related factors were assessed for association with outcomes using Gray's test and multivariable Cox models. The time period for all analyses began at 2 years postevaluation to restrict analyses to patients presumed to not have had SC present at evaluation. Nineteen patients were diagnosed with NMSC and 19 were diagnosed with cancers other than NMSC, with 10-year cumulative incidences of 15.5% (95% confidence interval, 9.0% to 27.6%) and 13.8% (95% CI, 8.2% to 20.8%), respectively. Age at transplantation (hazard ratio [HR], 1.94; 95% CI, 1.23 to 3.06) and higher C-reactive protein level at evaluation (HR, 9.49; 95% CI, 1.26 to 71.58) were jointly associated with NMSC, and gastrointestinal cGVHD at evaluation (HR, 0.26; 95% CI, 0.09 to 0.78) was associated with reduced risk of NMSC. T cell depletion at transplantation (HR, 3.09; 95% CI, 1.17 to 8.20), lymphoma as an indication for transplantation (HR, 3.96; 95% CI, 1.56 to 10.05), and oral cGVHD severity at evaluation (HR, 4.36; 95% CI, 1.52 to 12.46) were jointly associated with cancers other than NMSC. This study estimates the incidence of SC in a population of allo-HSCT recipients with severe cGVHD and identifies correlations with the subsequent development of SC. These factors seem to differ between NMSC and cancers other than NMSC. Further longitudinal investigations accounting for dynamic and cumulative processes are needed to improve our understanding and management of SC.
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Chronic geaft-versus-host disease; Late effects; Subsequent cancer

Mesh:

Year:  2021        PMID: 34380090      PMCID: PMC8556294          DOI: 10.1016/j.jtct.2021.08.001

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  29 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

Review 2.  Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.

Authors:  Taha Al-Juhaishi; Arushi Khurana; Danielle Shafer
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-16       Impact factor: 3.020

3.  Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

Authors:  A Sureda; R Arranz; A Iriondo; E Carreras; J J Lahuerta; J García-Conde; I Jarque; M D Caballero; C Ferrà; A López; J García-Laraña; R Cabrera; D Carrera; M D Ruiz-Romero; A León; J Rifón; J Díaz-Mediavilla; R Mataix; M Morey; J M Moraleda; A Altés; A López-Guillermo; J de la Serna; J M Fernández-Rañada; J Sierra; E Conde
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.

Authors:  Y Atsuta; R Suzuki; T Yamashita; T Fukuda; K Miyamura; S Taniguchi; H Iida; T Uchida; K Ikegame; S Takahashi; K Kato; K Kawa; T Nagamura-Inoue; Y Morishima; H Sakamaki; Y Kodera
Journal:  Ann Oncol       Date:  2014-01-07       Impact factor: 32.976

6.  Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study.

Authors:  Claire M Vajdic; Eleni Mayson; Anthony J Dodds; Tracey O'Brien; Leonie Wilcox; Ian Nivison-Smith; Renate Le Marsney; Benjamin Daniels; Lesley J Ashton
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-06       Impact factor: 5.742

7.  Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.

Authors:  Rochelle E Curtis; Catherine Metayer; J Douglas Rizzo; Gérard Socié; Kathleen A Sobocinski; Mary E D Flowers; William D Travis; Lois B Travis; Mary M Horowitz; H Joachim Deeg
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

8.  Solid cancers after allogeneic hematopoietic cell transplantation.

Authors:  J Douglas Rizzo; Rochelle E Curtis; Gérard Socié; Kathleen A Sobocinski; Ethel Gilbert; Ola Landgren; Lois B Travis; William D Travis; Mary E D Flowers; Debra L Friedman; Mary M Horowitz; John R Wingard; H Joachim Deeg
Journal:  Blood       Date:  2008-10-29       Impact factor: 22.113

9.  Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.

Authors:  Jacques Dantal; Emmanuel Morelon; Lionel Rostaing; Eric Goffin; Anabelle Brocard; Isabelle Tromme; Nilufer Broeders; Véronique Del Marmol; Valérie Chatelet; Anne Dompmartin; Michèle Kessler; Andreas Serra; Günther F L Hofbauer; Nassim Kamar; Claire Pouteil-Noble; Jean Kanitakis; Adeline Roux; Evelyne Decullier; Sylvie Euvrard
Journal:  J Clin Oncol       Date:  2018-07-17       Impact factor: 44.544

10.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Authors:  L Grkovic; K Baird; S M Steinberg; K M Williams; D Pulanic; E W Cowen; S A Mitchell; F T Hakim; K J Martires; D N Avila; T N Taylor; R B Salit; S D Rowley; D Zhang; D H Fowler; M R Bishop; R E Gress; S Z Pavletic
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

View more
  1 in total

1.  A rare case report of graft-versus-host disease-related cutaneous horns of the lower lip.

Authors:  Michaël Verquin; Christophe Politis; François Thonnart; Sabine Fransis; Serge Schepers
Journal:  JAAD Case Rep       Date:  2022-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.